June—Asuragen Inc. (diagnostics and pharmaceutical services) has licensed non-exclusive rights to Johns Hopkins University's BRAF V600E mutation sequence for use in molecular diagnostics for cancer.
BRAF mutation has been used as a genetic marker for various cancer types. JHU has found that detection of the...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?